Erudio Healtherudio.com
Clinical trial · no report yet · Phase not applicable
INTERVAL-GAP4 trial: what clinicians have said so far
INTense ExeRcise for SurviVAL Among Men with Metastatic Prostate Cancer (INTERVAL - GAP4)
- NCT02730338 ↗
- Unknown
- Movember Foundation
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on INTERVAL-GAP4 (metastatic prostate cancer; tests a strategy, not a drug) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on INTERVAL-GAP4 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 2 YouTube videos | |
| 2 posts on X |
The trial
ClinicalTrials.gov- Official title
- INTense ExeRcise for SurviVAL Among Men with Metastatic Prostate Cancer (INTERVAL - GAP4): a Multicentre, Randomised, Controlled, Phase III Study
- Phase
- Phase not applicable
- Status
- Unknown
- Conditions
- Metastatic Prostate Cancer
- Interventions
- High intensity aerobic and resistance training; Psychosocial support
- Arms
- Arm A: Supervised exercise group · Active comparator
- Arm B: Self directed exercise group · Other
- Enrollment
- 866 (estimated)
- Primary outcomes
- Overall Survival
- Sponsor
- Movember Foundation with University of California, San Francisco, Edith Cowan University, King's College London, Centre hospitalier de l'Université de Montréal (CHUM)
- Start
- Jan 2016
- Primary completion
- Oct 2025 (estimated)
- Results posted
- No
- Registry record
- NCT02730338 · updated Nov 27, 2024
Publications
linked from the registry- Umlauff L, Kenfield SA, Newton RU, Hart NH, Saad F, Courneya KS, Greenwood R, Bloch W; INTERVAL-GAP4 Steering Committee/Coordinating Centres Members/Protocol Development Working Group Members; Schumann M. Meeting Aerobic Physical Activity Guidelines and Associations With Physical Fitness in Men With Metastatic Prostate Cancer: Baseline Results of the Multicentre INTERVAL-GAP4 Trial. Cancer Med. 2024 Dec;13(23):e70261. doi: 10.1002/cam4.70261. PubMed 39632499
- Kim JS, Taaffe DR, Galvao DA, Clay TD, Redfern AD, Gray ES, Newton RU. Enhancing circulatory myokines and extracellular vesicle uptake with targeted exercise in patients with prostate cancer (the MYEX trial): a single-group crossover study. BMC Cancer. 2024 Jul 1;24(1):784. doi: 10.1186/s12885-024-12530-0. PubMed 38951803
- Newton RU, Kenfield SA, Hart NH, Chan JM, Courneya KS, Catto J, Finn SP, Greenwood R, Hughes DC, Mucci L, Plymate SR, Praet SFE, Guinan EM, Van Blarigan EL, Casey O, Buzza M, Gledhill S, Zhang L, Galvao DA, Ryan CJ, Saad F. Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol. BMJ Open. 2018 May 14;8(5):e022899. doi: 10.1136/bmjopen-2018-022899. PubMed 29764892